Work at Shanghai Haihe Biopharma Co. Ltd. has led to the development of pyrimidine-2(1H)-one-fused bicyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors and thus reported to be useful for the treatment of cancer.

Boehringer Ingelheim Pharma GmbH & Co. KG has prepared and tested heteroaromatic compounds described as GTPase KRAS G12C mutant inhibitors and reported to be useful for the treatment of cancer.

Immunic AG has identified deuterated dihydroorotate dehydrogenase (DHODH) inhibitors containing a carboxylic acid bioisostere. They are reported to be useful for the treatment of Crohn’s disease, influenza, lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, SARS-CoV-2 infection (COVID-19) and cancer, among others.

A Gossamer Bio Inc. patent describes oxime derivatives that act as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors and are thus reported to be useful for the treatment of cancer and viral infections.

The most in-depth study to date of the genetic risk factors for long COVID has identified 73 genes that are highly associated with severe or fatigue-dominant forms of the disease. Many of these genes also are known to be associated with other disorders, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and neurodegenerative, autoimmune, cardiovascular and metabolic diseases.